Breast cancer and hormonal therapy in postmenopausal women

Agnès Fournier, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon

To cite this version:

HAL Id: inserm-01320254
https://www.hal.inserm.fr/inserm-01320254
Submitted on 23 May 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Chlebowski et al. recently reported from the Women’s Health Initiative (WHI) that the risk of breast cancer associated with the use of combined menopausal hormone therapy (HT) markedly decreased after treatment discontinuation.\textsuperscript{1} With a similar approach to that used in the WHI observational-study cohort, we investigated whether that decrease was also seen in the French E3N cohort, in which HT use was biennially self-reported.\textsuperscript{2} Among postmenopausal respondents to the 1997-1998 questionnaire, those who were using combined HT or had never used HT at completion of the questionnaire were followed from January 1999 up to the date of diagnosis of any malignancy, last completed questionnaire, or July 2005, whichever occurred first. Hazard ratios of breast cancer for combined HT users vs. HT never-users (in 1997-1998) dramatically dropped towards unity after 2002, in parallel with an important reduction in HT use (Table 1). Our results in a French population therefore corroborate those from the North-American WHI setting and strengthen suggestions of a marked and rapid decline of breast cancer risk after discontinuation of combined HT.\textsuperscript{3}

Agnès Fournier, Ph.D.
Marie-Christine Boutron-Ruault, M.D., Ph.D.
Françoise Clavel-Chapelon, Ph.D.
Inserm ERI-20
Institut Gustave Roussy
F-94805 Villejuif Cedex
France
Email: clavel@igr.fr
Fax number: +33 1 42 11 40 00
Phone number: +33 1 42 11 41 48

References
Table 1. Year-to-year hazard ratios of invasive breast cancer for users of combined HT in 1997-1998 compared with HT never-users in 1997-1998; year-to-year percentage of HT current users. E3N study

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. at risk</td>
<td>Mean follow-up (mo)</td>
<td>No. of cases</td>
<td>Annualized incidence (%)</td>
<td>Hazard ratio (95% CI) †</td>
<td>Hazard ratio (95% CI) with adjustment for prior mammograms‡</td>
<td>% current HT users§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>25,689</td>
<td>11.9</td>
<td>147</td>
<td>0.58</td>
<td>1.87 (1.33-2.62)</td>
<td>1.87 (1.32-2.64)</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>18,107</td>
<td>11.9</td>
<td>54</td>
<td>0.30</td>
<td>2.31 (1.61-3.30)</td>
<td>2.41 (1.66-3.48)</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>25,430</td>
<td>11.9</td>
<td>133</td>
<td>0.53</td>
<td>1.81 (1.30-2.52)</td>
<td>1.82 (1.30-2.55)</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>24,683</td>
<td>11.9</td>
<td>49</td>
<td>0.28</td>
<td>1.92 (1.39-2.64)</td>
<td>1.93 (1.39-2.67)</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>24,233</td>
<td>11.6</td>
<td>147</td>
<td>0.35</td>
<td>1.22 (0.89-1.68)</td>
<td>1.19 (0.87-1.64)</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>21,939</td>
<td>11.5</td>
<td>160</td>
<td>0.43</td>
<td>1.10 (0.80-1.53)</td>
<td>1.08 (0.78-1.51)</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005*</td>
<td>21,106</td>
<td>11.8</td>
<td>125</td>
<td>0.53</td>
<td>1.22 (0.75-1.98)</td>
<td>1.17 (0.72-1.91)</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; HT, menopausal hormone therapy

* Data were included until July 2005
† Cox proportional-hazards model adjusted for: age (time scale), age at menopause (continuous), type of menopause (artificial / natural or unknown), parity and age at first full-term pregnancy (nulliparous / first full-term pregnancy at age <30, 1 or 2 children / first full-term pregnancy at age <30, 3 or more children / first full-term pregnancy at age ≥30), personal history of benign breast disease before menopause (yes / no), family history of breast cancer in first-degree relatives (yes / no), family history of breast cancer in other relatives (yes / no), body mass index before menopause (≤20 / [20-25] / [25-30] / >30 kg/m²), physical activity in 1990 (<27 / [27-39] / [39-57] / ≥ 57 metabolic equivalent task-hour/week), use of oral progestagens before menopause (never / in the past 5 years / more than 5 years ago / ever, but unknown recency), use of oral contraceptives (never / in the past 5 years / more than 5 years ago / ever, but unknown recency). Further stratified on year of birth ([1925-1930]/[1930-1935]/[1935-1940]/[1940-1945]/[1945-1950])
‡ Cox proportional-hazards model adjusted for the same variables as in footnote (†), with further adjustment on mammography during the previous follow-up period (yes / no, time-dependant variable)
§ At the end of the year (or July 2005 for year 2005)